Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Aptorum

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              HONG KONG Hong Kong

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              euroPLX 74 Athens

              Participation Not Confirmed

              Update your events

              Aptorum Group Announces Further Positive Data on ALS-4 Against MRSA Wound Infection and MRSA Bacteraemia Against Linezolid and Vancomycin Re...

              Contact the Supplier

              Lead Product(s): ALS-4

              Therapeutic Area: Infections and Infectious Diseases Product Name: ALS-4

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 01, 2020

              Details:

              Two sets of positive data showing both significant in vivo activities of its lead compound ALS-4 against Methicillin-Resistant Staphylococcus aureus in wound infected and bacteraemia mouse models, respectively when compared to prevailing antibiotics.

              Aptorum

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              HONG KONG Hong Kong

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              euroPLX 74 Athens

              Participation Not Confirmed

              Update your events

              Aptorum Group Announces Further Positive Data For Its ALS-4

              Contact the Supplier

              Lead Product(s): ALS-4

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 10, 2020

              Details:

              Subject to completion of the current studies, Aptorum Group targets to submit IND for ALS-4 in second half of 2020 and commence a phase 1 trial in North America.

              PharmaCompass__DigitalAd